News
AbbVie CEO Rob Michael said the company will invest $10 billion in the US over the next decade, as the threat of ...
Akeso Biopharma won first-line approval in China for its lung cancer drug ivonescimab, a new immunotherapy that it believes ...
HHS Secretary Robert F. Kennedy Jr. said Friday that 35 states had signed up to participate in a new payment model meant to ...
Amgen is the latest in a series of biopharma companies to tout a massive new US-based investment in manufacturing.
A federal district court in Texas on Thursday denied a request for a preliminary injunction from the Outsourcing Facilities ...
ALX Oncology’s efforts to progress a CD47 combo hit a major speed bump. The company said Friday that two trials ...
Endpoints Weekly covers Q1 earnings from major pharma companies, with focus on tariff concerns. FDA's Makary discusses new rare disease pathway, and HuidaGene reports first brain CRISPR treatment.
Nicholas Johnston launches Alis Biosciences, targeting struggling biotechs with $30B in trapped capital and aiming to return ...
When the board of Belgian biotech Galapagos asked Paul Stoffels to become CEO, he told them he was only interested in doing ...
Merck KGaA in talks to acquire SpringWorks Therapeutics for $47/share ($3.5B), gaining cancer drugs Ogsiveo and Gomekli. Deal ...
Sanofi reports Q1 growth with Altuviiio sales doubling to €251M and Dupixent reaching €3.5B; company terminates two cancer ...
Caribou Biosciences is paring down its pipeline and cutting about a third of its workforce as cell and gene therapy companies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results